Connect Biopharma Holdings Stock Performance
| CNTB Stock | USD 0.92 0.05 5.15% |
The firm shows a Beta (market volatility) of -0.14, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Connect Biopharma are expected to decrease at a much lower rate. During the bear market, Connect Biopharma is likely to outperform the market. Connect Biopharma right now shows a risk of 5.19%. Please confirm Connect Biopharma sortino ratio, skewness, price action indicator, as well as the relationship between the potential upside and rate of daily change , to decide if Connect Biopharma will be following its price patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Connect Biopharma Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Connect Biopharma is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 79 M |
Connect |
Connect Biopharma Relative Risk vs. Return Landscape
If you would invest 98.00 in Connect Biopharma Holdings on November 19, 2024 and sell it today you would lose (5.80) from holding Connect Biopharma Holdings or give up 5.92% of portfolio value over 90 days. Connect Biopharma Holdings is currently generating 0.0304% in daily expected returns and assumes 5.1855% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than Connect, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Connect Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Connect Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Connect Biopharma Holdings, and traders can use it to determine the average amount a Connect Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0059
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CNTB |
Estimated Market Risk
| 5.19 actual daily | 46 54% of assets are more volatile |
Expected Return
| 0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Connect Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Connect Biopharma by adding Connect Biopharma to a well-diversified portfolio.
Connect Biopharma Fundamentals Growth
Connect Stock prices reflect investors' perceptions of the future prospects and financial health of Connect Biopharma, and Connect Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Connect Stock performance.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.89) % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | (58.88 M) | ||||
| Shares Outstanding | 55.25 M | ||||
| Price To Book | 0.46 X | ||||
| Price To Sales | 2.11 X | ||||
| EBITDA | (58.37 M) | ||||
| Cash And Equivalents | 1.28 B | ||||
| Cash Per Share | 23.26 X | ||||
| Total Debt | 465 K | ||||
| Debt To Equity | 0 % | ||||
| Book Value Per Share | 2.00 X | ||||
| Cash Flow From Operations | (47.93 M) | ||||
| Earnings Per Share | (0.39) X | ||||
| Total Asset | 125.89 M | ||||
| Retained Earnings | (539.35 M) | ||||
About Connect Biopharma Performance
By analyzing Connect Biopharma's fundamental ratios, stakeholders can gain valuable insights into Connect Biopharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Connect Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Connect Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company was founded in 2012 and is headquartered in Taicang, China. Connect Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 108 people.Things to note about Connect Biopharma performance evaluation
Checking the ongoing alerts about Connect Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Connect Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Connect Biopharma had very high historical volatility over the last 90 days | |
| Connect Biopharma has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (59.38 M) with profit before overhead, payroll, taxes, and interest of 24.12 M. | |
| Connect Biopharma Holdings currently holds about 1.28 B in cash with (47.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Connect Biopharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 41.0% of the company shares are held by company insiders |
- Analyzing Connect Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Connect Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Connect Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Connect Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Connect Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Connect Biopharma's stock. These opinions can provide insight into Connect Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Connect Stock analysis
When running Connect Biopharma's price analysis, check to measure Connect Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Connect Biopharma is operating at the current time. Most of Connect Biopharma's value examination focuses on studying past and present price action to predict the probability of Connect Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Connect Biopharma's price. Additionally, you may evaluate how the addition of Connect Biopharma to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Stocks Directory Find actively traded stocks across global markets |